|
⚲
|
| Keyboard |
| Crestline Management LP
✚
|
|
|---|---|
| CRD # | 122711 |
| SEC # | 801-61607 |
| CIK # | 0001536054 |
| AUM | 22.51 B (2026-03-30) |
| Employees | 195 (58% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 817-339-7600 |
| Address | 201 Main Street Fort Worth, TX 76102-3135 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($B) |
|---|
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| Denali Therapeutics Inc | 0.0 | ||
| SANA Biotechnology Inc | 0.0 | ||
| 8X8 Inc /DE/ | 0.0 | ||
| Holdings by Sector ($B) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| HF | CL AK Broadstreet LP | 2026-02-27 | 101.4 M | |
| HF | CL Meadow LLC | 2026-02-27 | 24.5 M | |
| HF | Crestline European Capital Solutions Fund II SCSP | [2025-03-31] | 157.7 M | 458.6 M |
| Filed 2025-10-24 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $5,000,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Crestline Portfolio Financing Fund III SCSP | [2025-03-31] | 325.2 M | 424.7 M |
| Filed 2025-11-26 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $5,000,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | CL FLS 1 LP | 2025-02-28 | 3.2 M | |
| HF | CL Green Park LP | [2024-11-27] | 81.4 M | |
| Filed 2024-07-15 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Net Assets Decline to Disclose | ||||
| HF | Crestline Lending Solutions LLC | [2024-11-27] | 219.1 M | |
| Filed 2024-08-08 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Net Assets Decline to Disclose | ||||
| HF | Crestline Structured Note Issuer I LLC | 2024-08-29 | 291.2 M | |
| Other | Dynamite LP | 2024-08-29 | 10.1 M | |
| HF | CL Nevermore LP | [2024-02-29] | 37.7 M | |
| Filed 2023-11-08 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Net Assets Decline to Disclose | ||||
| View All | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 1 | 0.5 |
| (f) Pooled investment vehicles | 100 | 12.6 |
| (g) Pension and profit sharing plans | 9 | 4.8 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.8 |
| (j) Other investment advisers | 0 | 0.1 |
| (k) Insurance companies | 5 | 2.6 |
| (l) Sovereign wealth funds and foreign official institutions | 16 | 0.9 |
| (m) Corporations or other businesses not listed above | 0 | 0.1 |
| (n) Other | 0 | 0.0 |
| Total | 135 | 22.5 |
| By Discretionary | ||
| Discretionary | 135 | 22.5 |
| Non-Discretionary | 0 | 0.0 |
| Total | 135 | 22.5 |
| By Non-United States Persons | ||
| Non-United States Persons | 16.2 | |
| United States Persons | 6.3 | |
| Total | 135 | 22.5 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Karla Bodden | Director | 186 | 22 | |
| J Hunter | Director | 61 | 13 | |
| Dennis Hunter | Director | 132 | 12 | |
| Darren Gorman | Director | 127 | 8 | |
| Jane Fleming | Director | 26 | 8 | |
| Robert Watson | Executive Officer | 54 | 5 | |
| Maurice Murphy | Director | 8 | 5 | |
| Therese Collins | Director | 7 | 5 | |
| Crestline Management LP | Executive Officer, Promoter | 93 | 4 | |
| Kevin Ryan | Director | 63 | 4 | |
| Douglas Bratton | Director, Executive Officer | 22 | 4 | |
| Tilly Directors Limited | Director | 10 | 4 | |
| Crestline Investors Inc | Executive Officer, Promoter | 55 | 3 | |
| Crestline Associates LP | Executive Officer, Promoter | 18 | 3 | |
| Scott Nelson | Executive Officer | 18 | 3 | |
| Caroline Cooley | Executive Officer | 7 | 3 | |
| Summittx Capital LP | Executive Officer | 6 | 3 | |
| Alex Didych | Executive Officer | 6 | 3 | |
| Robert Lyster | Executive Officer | 6 | 3 | |
| Neilson Arbour | Executive Officer | 6 | 3 | |
| Brian Peller | Executive Officer | 6 | 3 | |
| Keith Williams | Executive Officer | 5 | 3 | |
| Crestline Offshore Associates Ltd | Executive Officer | 9 | 2 | |
| Crestline Opportunity V GP LLC | Executive Officer | 3 | 2 | |
| Crestline Direct Lending Ul GP LLC | Executive Officer | 3 | 2 | |
| Crestline Portfolio Financing Fund III Lux GP Sa RL | Executive Officer | 3 | 2 | |
| Crestline Opportunity IV GP LLC | Executive Officer | 3 | 2 | |
| Rahul Vaid | Executive Officer | 3 | 2 | |
| Crestline Direct Lending IV Feeder GP LLC | Executive Officer | 2 | 2 | |
| Summittx GP LP | Executive Officer | 2 | 2 | |
| Crestline Summit GP LP | Executive Officer | 2 | 2 | |
| Crestline Portfolio Financing Fund II GP LLC | Executive Officer | 2 | 2 | |
| Crestline European Capital Solutions Fund II GP Sa RL | Executive Officer | 2 | 2 | |
| Crestline Specialty Lending II GP Ltd | Executive Officer | 2 | 2 | |
| Shawn Hessing | Executive Officer | 2 | 2 | |
| Crestline Specialty Lending GP Ltd | Executive Officer | 2 | 2 | |
| Crestline Praeter GP LLC | Executive Officer | 5 | 1 | |
| Crestline Associates III LP | Executive Officer, Promoter | 4 | 1 | |
| CL Oliver GP LLC | Executive Officer | 2 | 1 | |
| Siobhan Moloney | Director | 1 | 1 | |
| Crestline Horizon GP LP | Executive Officer | 1 | 1 | |
| Crestline Sundance GP LP | Executive Officer | 1 | 1 | |
| Crestline StepStone Opportunistic Credit GP LLC | Executive Officer | 1 | 1 | |
| Crestline PF Sentry Fund Lux GP Sa RL | Executive Officer | 1 | 1 | |
| Crestline Opportunity Fund Sma GP LLC | Executive Officer | 1 | 1 | |
| Gary Bader | Director | 1 | 1 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001536054] | |
| 13F-NT | [0001536054] | |
| 3 | [0001536054] | |
| 4 | [0001536054] |
| Firm Profile (Form ADV) | |
|---|---|
| Discretionary AUM | $6.4B |
| Serves | Institutional |
| Fund Types | Hedge Fund, Private Equity |
| LEI | 5ZQYRF3Z9W001NF39K35 |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Midwest Holding Inc MDWT
Voting Common Stock
|
2022-06-14 | Grant | 2,674 | $0.00 | |
|
Midwest Holding Inc MDWT
Voting Common Stock
|
2021-11-11 | Grant | 727 | $0.00 | |
|
Denali Therapeutics Inc DNLI
Common Stock
|
2021-02-12 | Sell | 2,216,798 | $65.00 | 144,091,870 |
|
Denali Therapeutics Inc DNLI
Common Stock
|
2020-08-12 | Sell | 1,443,247 | $31.65 | 45,678,768 |
|
Midwest Holding Inc MDWT
Stock Option (right to buy) · derivative
|
2020-07-31 | Grant | 50,000 | $0.00 | |
|
Denali Therapeutics Inc DNLI
Common Stock
|
2020-06-05 | Sell | 1,922,855 | $25.75 | 49,513,516 |
|
Denali Therapeutics Inc DNLI
Common Stock
|
2020-02-26 | Sell | 3,894,764 | $20.25 | 78,868,971 |
|
Denali Therapeutics Inc DNLI
Common Stock
|
2017-12-12 | Conversion | 14,499,999 | ||
|
Denali Therapeutics Inc DNLI
Common Stock
|
2017-12-12 | Conversion | 2,500,000 | ||
|
Denali Therapeutics Inc DNLI
Series A-1 Convertible Preferred Stock · derivative
|
2017-12-12 | Conversion | 14,499,999 | $0.00 | |
|
Denali Therapeutics Inc DNLI
Series A-1 Convertible Preferred Stock · derivative
|
2017-12-12 | Conversion | 743,599 | $0.00 | |
|
Denali Therapeutics Inc DNLI
Series B-1 Convertible Preferred Stock · derivative
|
2017-12-12 | Conversion | 1,875,000 | $0.00 | |
|
Denali Therapeutics Inc DNLI
Series A-2 Convertible Preferred Stock · derivative
|
2017-12-12 | Conversion | 2,500,000 | $0.00 | |
|
Denali Therapeutics Inc DNLI
Series B-1 Convertible Preferred Stock · derivative
|
2017-12-12 | Conversion | 240,000 | $0.00 | |
|
Denali Therapeutics Inc DNLI
Series A-2 Convertible Preferred Stock · derivative
|
2017-12-12 | Conversion | 128,200 | $0.00 | |
|
Denali Therapeutics Inc DNLI
Common Stock
|
2017-12-12 | Conversion | 240,000 | ||
|
Denali Therapeutics Inc DNLI
Common Stock
|
2017-12-12 | Buy | 275,000 | $18.00 | 4,950,000 |
|
Denali Therapeutics Inc DNLI
Common Stock
|
2017-12-12 | Conversion | 128,200 | ||
|
Denali Therapeutics Inc DNLI
Common Stock
|
2017-12-12 | Conversion | 743,599 | ||
|
Denali Therapeutics Inc DNLI
Common Stock
|
2017-12-12 | Conversion | 1,875,000 | ||
| showing 20 of 33 most recent transactions | |||||
| Comparable Firms | State | AUM |
|---|---|---|
|
Strategic Value Partners LLC
✚
|
CT | 25.61 B |
|
KSL Advisors LLC
✚
|
CO | 25.61 B |
|
Providence Equity Partners LLC
✚
|
RI | 24.12 B |
|
Templeton Asset Management Ltd
✚
|
24.05 B | |
|
New Holland Capital LLC
✚
|
NY | 23.32 B |
|
Benefit Street Partners Limited
✚
|
22.61 B | |
|
Dawson Partners Inc
✚
|
22.14 B | |
|
Lone Pine Capital LLC
✚
|
CT | 21.62 B |
|
OrbiMed Advisors LLC
✚
|
NY | 20.61 B |
|
Hildene Capital Management LLC
✚
|
CT | 20.18 B |